SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
KRX:302440
Price:
37 650
KRW
-4.44%
Market Closed
Market Cap:
2.9T
KRW
Balance Sheet
Balance Sheet Decomposition
SK Bioscience Co Ltd
SK Bioscience Co Ltd
| Current Assets | 1.6T |
| Cash & Short-Term Investments | 1.2T |
| Receivables | 188.4B |
| Other Current Assets | 231.8B |
| Non-Current Assets | 1.3T |
| Long-Term Investments | 29.1B |
| PP&E | 982.6B |
| Intangibles | 124.5B |
| Other Non-Current Assets | 130.7B |
Balance Sheet
SK Bioscience Co Ltd
SK Bioscience Co Ltd
Currency: KRW
Millions
Annual
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
4 489
|
14 380
|
24 972
|
98 028
|
225 287
|
127 026
|
312 702
|
|
| Cash Equivalents |
4 489
|
14 380
|
24 972
|
98 028
|
225 287
|
127 026
|
312 702
|
|
| Short-Term Investments |
99 189
|
80 088
|
183 736
|
1 547 635
|
1 250 218
|
1 141 816
|
843 807
|
|
| Total Receivables |
43 472
|
32 429
|
54 008
|
48 135
|
89 661
|
22 342
|
188 396
|
|
| Accounts Receivables |
42 873
|
32 241
|
31 476
|
39 027
|
41 059
|
18 235
|
105 894
|
|
| Other Receivables |
599
|
188
|
22 532
|
9 107
|
48 602
|
4 108
|
82 502
|
|
| Inventory |
31 876
|
36 378
|
70 275
|
135 046
|
187 406
|
80 649
|
211 126
|
|
| Other Current Assets |
1 703
|
7 465
|
911
|
8 960
|
31 122
|
11 136
|
20 643
|
|
| Total Current Assets |
180 729
|
170 741
|
333 902
|
1 837 804
|
1 783 694
|
1 382 969
|
1 576 673
|
|
| PP&E Net |
172 831
|
190 770
|
189 479
|
220 983
|
293 057
|
315 923
|
982 607
|
|
| Intangible Assets |
21 839
|
19 479
|
17 858
|
17 061
|
18 181
|
22 459
|
67 112
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
57 436
|
|
| Note Receivable |
10 985
|
10 597
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
86
|
86
|
86
|
586
|
1 586
|
42 815
|
29 115
|
|
| Other Long-Term Assets |
13 528
|
12 307
|
20 907
|
33 688
|
45 413
|
88 273
|
130 653
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
57 436
|
|
| Total Assets |
399 997
N/A
|
403 980
+1%
|
562 232
+39%
|
2 110 123
+275%
|
2 141 931
+2%
|
1 852 439
-14%
|
2 843 596
+54%
|
|
| Liabilities | ||||||||
| Accounts Payable |
11 077
|
18 372
|
17 505
|
63 812
|
11 053
|
3 370
|
17 818
|
|
| Accrued Liabilities |
4 550
|
7 094
|
11 520
|
26 322
|
30 242
|
19 716
|
54 298
|
|
| Short-Term Debt |
0
|
0
|
0
|
11 671
|
45 550
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
11 411
|
1 351
|
12 608
|
50 287
|
50 243
|
8 137
|
6 957
|
|
| Other Current Liabilities |
23 572
|
18 692
|
139 006
|
307 860
|
242 949
|
104 397
|
231 518
|
|
| Total Current Liabilities |
50 610
|
45 509
|
180 639
|
459 952
|
380 037
|
135 620
|
310 589
|
|
| Long-Term Debt |
126 550
|
123 721
|
109 359
|
44 277
|
17 543
|
12 436
|
385 857
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
71 960
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
219 887
|
|
| Other Liabilities |
3 592
|
2 015
|
8 443
|
4 581
|
2 649
|
528
|
52 737
|
|
| Total Liabilities |
180 751
N/A
|
171 246
-5%
|
298 442
+74%
|
508 811
+70%
|
400 229
-21%
|
148 584
-63%
|
1 041 031
+601%
|
|
| Equity | ||||||||
| Common Stock |
10 200
|
10 200
|
30 600
|
38 250
|
38 392
|
38 414
|
39 174
|
|
| Retained Earnings |
9 043
|
22 308
|
53 236
|
405 305
|
533 378
|
549 421
|
499 757
|
|
| Additional Paid In Capital |
201 245
|
201 545
|
181 419
|
1 157 064
|
1 160 008
|
1 160 456
|
1 235 376
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
54 727
|
6 652
|
|
| Other Equity |
1 242
|
1 319
|
1 465
|
693
|
9 924
|
10 292
|
21 606
|
|
| Total Equity |
219 246
N/A
|
232 734
+6%
|
263 790
+13%
|
1 601 312
+507%
|
1 741 702
+9%
|
1 703 855
-2%
|
1 802 565
+6%
|
|
| Total Liabilities & Equity |
399 997
N/A
|
403 980
+1%
|
562 232
+39%
|
2 110 123
+275%
|
2 141 931
+2%
|
1 852 439
-14%
|
2 843 596
+54%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
61
|
61
|
61
|
77
|
77
|
77
|
78
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
